451 reports of this reaction
3.3% of all CLADRIBINE reports
#4 most reported adverse reaction
MULTIPLE SCLEROSIS RELAPSE is the #4 most commonly reported adverse reaction for CLADRIBINE, manufactured by EMD Serono, Inc.. There are 451 FDA adverse event reports linking CLADRIBINE to MULTIPLE SCLEROSIS RELAPSE. This represents approximately 3.3% of all 13,464 adverse event reports for this drug.
Patients taking CLADRIBINE who experience multiple sclerosis relapse should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE SCLEROSIS RELAPSE is moderately reported among CLADRIBINE users, representing a notable but not dominant share of adverse events.
In addition to multiple sclerosis relapse, the following adverse reactions have been reported for CLADRIBINE:
The following drugs have also been linked to multiple sclerosis relapse in FDA adverse event reports:
MULTIPLE SCLEROSIS RELAPSE has been reported as an adverse event in 451 FDA reports for CLADRIBINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE SCLEROSIS RELAPSE accounts for approximately 3.3% of all adverse event reports for CLADRIBINE, making it a notable side effect.
If you experience multiple sclerosis relapse while taking CLADRIBINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.